Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Linezolid is an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the 70S initiation complex.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Treatment of vancomycin-resistant Enterococcus faecium infections including bacteremia,Treatment of nosocomial pneumonia caused by Staphylococcus aureus or Streptococcus pneumoniae,Treatment of complicated skin and skin structure infections including diabetic foot infections,Treatment of uncomplicated skin and skin structure infections,Treatment of community-acquired pneumonia,Off-label: Treatment of Nocardia infections, tuberculosis as part of combination therapy, and prosthetic joint infections
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
600 mg IV every 12 hours for 10-14 days.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Terminal elimination half-life is approximately 5.5 hours; in patients with severe renal impairment (Cr Cl <30 m L/min), half-life may be prolonged to 7-8 hours.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Linezolid is primarily metabolized by oxidation of the morpholine ring to form two inactive metabolites: aminoethoxyacetic acid and hydroxyethyl glycine. The exact enzyme system is not fully characterized, but it is believed to be non-enzymatic or via minor cytochrome P450 pathways.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Renal excretion accounts for approximately 30% of the dose as unchanged drug; nonrenal clearance (likely hepatic metabolism) accounts for about 70%. Fecal excretion is minimal (<2%).
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Approximately 31% bound to plasma proteins, primarily albumin (about 29%) and alpha-1-acid glycoprotein (about 10%).
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Steady-state volume of distribution is approximately 0.7 L/kg, indicating extensive distribution into well-perfused tissues (e.g., lungs, skin, muscle, and bone).
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Oral bioavailability is approximately 100%, with a 600 mg oral tablet yielding AUC equivalent to a 30-minute IV infusion of 600 mg.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
No dose adjustment required for any degree of renal impairment. However, the two primary metabolites may accumulate in severe renal impairment, but clinical significance is unknown.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No dose adjustment required for mild-to-moderate hepatic impairment (Child-Pugh A or B). Insufficient data for severe hepatic impairment (Child-Pugh C); use with caution.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Neonates and children <12 years: 10 mg/kg IV every 8 hours for 10-14 days. Children ≥12 years: same as adult dosing.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
No specific dose adjustment based on age alone. Monitor renal function as clearance may decrease with age, but no dose change recommended.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
Linezolid is not approved for the treatment of catheter-related bloodstream infections or catheter-site infections. An increased risk of mortality was seen in patients with catheter-related bloodstream infections in a clinical trial.
None
Myelosuppression including anemia, leukopenia, thrombocytopenia, and pancytopenia,Peripheral and optic neuropathy,Lactic acidosis,Serotonin syndrome when coadministered with serotonergic agents,Convulsions,Clostridium difficile-associated diarrhea,Hypoglycemia in diabetic patients,Development of drug-resistant bacteria,Use in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or hyperthyroidism due to tyramine interactions
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Known hypersensitivity to linezolid or any component of the formulation,Concomitant use within 2 weeks of monoamine oxidase inhibitors (MAOIs)
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
Avoid tyramine-containing foods and beverages to reduce risk of hypertensive crisis. Examples: aged cheeses (cheddar, blue cheese), cured/smoked meats (pepperoni, salami), fermented foods (sauerkraut, kimchi), soy products (tofu, miso), tap beers, red wines (Chianti), and overripe fruits (avocado, bananas). Patients should adhere to a low-tyramine diet during therapy and for 2 weeks after discontinuation.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Linezolid is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetal toxicity (reduced fetal weights, increased incidence of rib and vertebral anomalies) at doses approximately equivalent to the maximum human exposure. There are no adequate and well-controlled studies in pregnant women. In the first trimester, use only if potential benefit justifies potential risk to the fetus. In the second and third trimesters, limited data suggest no increased risk of major malformations, but potential for fetal effects due to maternal toxicity exists.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Linezolid is excreted in human milk. The milk-to-plasma (M/P) ratio is approximately 0.8. The estimated infant dose is about 1.3-1.4 mg/kg/day, which is less than 5% of the maternal therapeutic dose. However, due to potential for adverse effects (e.g., myelosuppression, peripheral neuropathy), caution is advised. Breastfeeding is not recommended during therapy and for 2-3 half-lives (approximately 12-18 hours) after the last dose.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Physiologic changes in pregnancy (increased volume of distribution, increased renal clearance) may affect linezolid pharmacokinetics. However, no formal dose adjustment studies in pregnancy. Standard adult dosing (600 mg IV or PO every 12 hours) is generally used. Consider monitoring serum levels (therapeutic trough 2-8 mcg/m L) if available, especially in severe infections. Dose adjustments may be necessary based on renal function (creatinine clearance <30 m L/min) but pregnancy-specific adjustments not established.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Linezolid is a reversible nonselective monoamine oxidase inhibitor (MAOI). Avoid concomitant use with serotonergic agents (e.g., SSRIs, SNRIs, triptans) due to risk of serotonin syndrome. Monitor for myelosuppression (especially thrombocytopenia) with prolonged therapy; complete blood counts should be checked weekly. Use with caution in uncontrolled hypertension, pheochromocytoma, or carcinoid syndrome due to potential for pressor response. Linezolid exhibits 100% oral bioavailability; intravenous form is used when oral route is not feasible.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
Avoid tyramine-rich foods and beverages (e.g., aged cheeses, cured meats, fermented products, tap beers, red wine) to prevent hypertensive crisis.,Report any signs of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle twitching) or bleeding (easy bruising, petechiae).,Take exactly as prescribed; do not stop without consulting your doctor even if you feel better.,Inform all healthcare providers that you are taking linezolid, especially before surgery or receiving any new medications.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Procaterol, a beta-2 adrenergic agonist, may enhance the hypertensive effects of linezolid, an oxazolidinone antibiotic that acts as a weak, reversible monoamine oxidase inhibitor (MAOI). This additive effect on blood pressure results from increased sympathetic tone, potentially leading to hypertensive crises. Patients may experience elevated systolic and diastolic blood pressure, tachycardia, and in severe cases, hypertensive urgency or emergency, especially when systemic absorption occurs from inhaled procaterol."
"Linezolid is a reversible, nonselective monoamine oxidase inhibitor (MAOI) that inhibits the metabolism of sympathomimetic amines such as phenylpropanolamine. This leads to increased concentrations of phenylpropanolamine and enhanced adrenergic stimulation, resulting in elevated blood pressure and risk of hypertensive crisis. Clinically, patients may experience severe hypertension, tachycardia, headache, and potential end-organ damage."
"Desipramine, a tricyclic antidepressant, inhibits the reuptake of serotonin and norepinephrine, increasing their synaptic concentrations. Linezolid, an oxazolidinone antibiotic, is a reversible, nonselective monoamine oxidase inhibitor (MAOI). Co-administration can lead to excessive serotonergic activity, potentially causing serotonin syndrome, a life-threatening condition characterized by agitation, hyperthermia, autonomic instability, neuromuscular rigidity, and altered mental status."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Linezolid is an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the 70S initiation complex.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 600 mg IV every 12 hours for 10-14 days.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Linezolid is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetal toxicity (reduced fetal weights, increased incidence of rib and vertebral an. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.